Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProPhase Labs (PRPH) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for ProPhase Labs (PRPH) over the last 16 years, with Sep 2025 value amounting to $405,000.

  • ProPhase Labs' Cash & Equivalents fell 19.16% to $405,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $405,000, marking a year-over-year decrease of 19.16%. This contributed to the annual value of $678,000 for FY2024, which is 57.86% down from last year.
  • Latest data reveals that ProPhase Labs reported Cash & Equivalents of $405,000 as of Q3 2025, which was up 139.64% from $169,000 recorded in Q2 2025.
  • ProPhase Labs' Cash & Equivalents' 5-year high stood at $32.7 million during Q1 2021, with a 5-year trough of $88,000 in Q1 2025.
  • Moreover, its 3-year median value for Cash & Equivalents was $702,000 (2023), whereas its average is $1.9 million.
  • Per our database at Business Quant, ProPhase Labs' Cash & Equivalents surged by 4,595.41% in 2021 and then plummeted by 97.35% in 2023.
  • Over the past 5 years, ProPhase Labs' Cash & Equivalents (Quarterly) stood at $8.4 million in 2021, then climbed by 8.34% to $9.1 million in 2022, then slumped by 82.34% to $1.6 million in 2023, then slumped by 57.86% to $678,000 in 2024, then dropped by 19.16% to $405,000 in 2025.
  • Its Cash & Equivalents was $405,000 in Q3 2025, compared to $169,000 in Q2 2025 and $88,000 in Q1 2025.